Canada Asthma and COPD Drugs Market Insight
Published: 02 June 2026 | Report Format: Electronic (PDF)
The Canada asthma and COPD drugs market size is rapidly expanding, at a 5.61% CAGR, and the biologics, inhalers, and digital respiratory therapies
Canada Asthma and COPD Drugs Market Insights Forecasts to 2035
- The Canada Asthma and COPD Drugs Market Size Was Estimated at USD 2.63 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.61% from 2025 to 2035
- The Canada Asthma and COPD Drugs Market Size is Expected to Reach USD 4.54 Billion by 2035
Notable Insights for Canada Asthma and COPD Drugs Market
- The combination inhaler segment accounts for roughly 48% market share in the asthma and COPD drugs market of the Canada owing to the presence of dual and triple therapies, patient adherence, and increased demand for respiratory treatments, backed by NHS England and £3.8 billion respiratory healthcare investments.
- The COPD application area contributes to approximately 42% demand share in the Canada owing to the prevalence of chronic respiratory diseases, growing aging population, and expansion of healthcare expenditures, backed by Asthma + Lung CANADA and £2.9 billion investments in pulmonary healthcare services.
- More than £190 billion annual investment is made by the Canada healthcare sector in promoting advanced respiratory treatments, biologic drugs, and precision medicine solutions, backed by CANADA Department of Health and Social Care and £6.2 billion respiratory innovations investments.
Download the eBook (ToC)
- The biological drugs segment captures approximately 24% demand share in the asthma and COPD drugs market of the Canada owing to the growing use of severe asthma treatment and targeted immunotherapies, backed by National Institute for Health and Care Excellence and £3.1 billion investments in biologic drugs.
Why Buy This Report
- Learn all about the CANADA market for asthma and COPD drugs which include combination inhalers, biological treatments, bronchodilators, corticosteroids, smart inhalers, and other advanced respiratory solutions.
- Discover how biological drugs, artificial intelligence-driven respiratory monitoring devices, digital inhalation systems, precision medicine, and connected health platforms are revolutionizing the CANADA asthma and COPD drugs sector.
- Find the best investment prospects in respiratory drugs, biological drug manufacturing, digital respiratory care solutions, smart inhalers, and pulmonary disease management.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Canada asthma and COPD drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Canada Asthma and COPD Drugs Market
- GlaxoSmithKline
- AstraZeneca
- Novartis
- Boehringer Ingelheim
- Sanofi
- Regeneron Pharmaceuticals
- Teva Pharmaceutical Industries
- Chiesi Farmaceutici
- Others
Recent Developments:
- In May 2026, UK-based AstraZeneca expanded its respiratory portfolio including BREZTRI inhaled combinations and biologics, supported by investments exceeding USD 2.3 billion, advancing chronic obstructive pulmonary disease (COPD) treatment, improving respiratory outcomes, and strengthening global inhalation therapy and biologics-driven pharmaceutical market growth.
- In May 2025, UK-based GSK plc in Canada advanced its portfolio in combination therapies and targeted biologics for severe disease phenotypes, supported by investments exceeding USD 3 billion, strengthening immunology and respiratory treatment pipelines and expanding global precision medicine and specialty pharmaceutical market growth.
Market Segmentation:
Canada Asthma and COPD Drugs Market, By Drug Class
- Bronchodilators
- Inhaled Corticosteroids
- Combination Therapies
- Biologics
- Others
Canada Asthma and COPD Drugs Market, By Disease Type
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Canada Asthma and COPD Drugs Market, By Route of Administration
- Inhalation
- Oral
- Injectable
- Others
Canada Asthma and COPD Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Expert Views:
The Canada Asthma and COPD Drugs Market is anticipated to experience significant growth in the coming years due to an increase in the prevalence of respiratory diseases, growing acceptance of biologics, and increased investment in advanced respiratory care solutions.
Author: Aditi and Govind By Spherical Insights and Consulting